Introduction {#Sec1}
============

Cellulite is a widespread problem involving the buttocks and thighs of the female-specific anatomy \[[@CR1]\]. The higher number of fat cells stored in female fatty tissue in contrast to males, the gender-specific dimorphism with subdermal septae orientated orthogonally toward the skin, and the aging process of connective tissue lead to an imbalance between lipogenesis and lipolysis with subsequent large fat cells bulging the skin \[[@CR1]\]. Recently, a case--control study in 15 lean women suffering from cellulite, and age- and body mass index (BMI)-matched controls identified significantly reduced adiponectin expression using reverse transcription polymerase chain reaction among the cellulite-affected patients \[[@CR2]\]. Cellulite appears to potentially impair quality of life of affected females substantially. It appears that younger females affected by cellulite suffer more in terms of impaired quality of life than more mature females \[[@CR3]\].

Non-randomized clinical data suggest that extracorporeal shock wave therapy (ESWT) is beneficial in terms of improved skin elasticity and revitalizing dermis in females with cellulite \[[@CR4], [@CR5]\]. Potentially, a direct effect on the associated lymphedema is a further potential consequence of ESWT application in cellulite. A recent Korean prospective clinical trial evaluated the effect of four ESWT sessions (0.056--0.068 mJ/mm^2^, 2,000 impulses, ESWT device from Dornier AB2) within 2 weeks in patients suffering from secondary lymphedema \[[@CR6]\]. Both the circumference and the thickness of the skin fold of the affected region were significantly reduced by as much as 37% in line with a pain reduction on the visual analogue scale \[[@CR6]\]. In systemic sclerosis, ESWT is able to again improve pain and the Rodnan skin score for skin wellness \[[@CR7]\].

To date, a limited number of non-controlled studies (two Level III \[[@CR4], [@CR8]\] and two Level IV studies \[[@CR9], [@CR10]\]) examined the effect of ESWT on cellulite with various outcome measures (Table [1](#Tab1){ref-type="table"}).Table 1Evidence levels of currently published clinical trials on the effect of extracorporeal shock wave therapy (ESWT) on cellulite with different outcome measures appliedAuthorYearNumber of patientsInterventionDeviceSessionsFollow-upOutcome measureResultDesignLevel of evidenceSiems et al. \[[@CR8]\]200526ESWT and/or physical decongestive therapy------Oxidative stress using malondialdehydeMitigation of oxidative stress of both interventionsCohort studyIIIAngehrn \[[@CR9]\]200721--------High resolution-ultrasound--Case seriesIVKuhn \[[@CR10]\]20081--ActiVitor-Derma (0.115 mJ/mm^2^, 200 pulses/cm^2^, 800 pulses)4 sessions--High resolution Ultrasound, histopathology by skin biopsyNeocollageno-genesis, increased dermal thicknessCase studyIVChrist \[[@CR4]\]200859----6 sessions in 15 patients, 8 sessions in 44 patients6 monthsDermascan ultrasound, DermaLab systemSkin elasticity improved by 105%Cohort studyIII--, not reported

Recently, a small size (*n* = 25) randomized-controlled trial (RCT) with large confidence intervals (CIs) has been published (level 2 evidence) \[[@CR11]\]. The trial involved six sessions over 4 weeks using the STORZ D-ACTOR^®^ 200 by Storz Medical (Tägerwilen, Switzerland) improved depressions, elevations, roughness, and elasticity within 3 months.

Beyond the aforementioned RCT \[[@CR11]\], with small sample size and large confidence intervals, we do not have any high-level 1b evidence to support the use of focused ESWT for non-invasive body contouring in cellulite. In addition, we do not know whether or not and if, to what extent the validated photo-numeric Cellulite Severity Scale (CSS) is changed by six sessions of focused ESWT. Currently, we do not have any high-level 1b evidence regarding the effect of gluteal home-based strength training with or without focused ESWT on the clinical outcome in cellulite in terms of digital images, microcirculation and patient self-reported assessment. Given these facts we sought to overcome these issues and performed a double-blinded, RCT providing level 1b evidence on the use of focused ESWT in addition to daily gluteal strength training in various degrees of cellulite. We hypothesized that the combination of ESWT and a daily gluteal muscle strength program is superior to SHAM-ESWT and a gluteal muscle strength program in cellulite.

Methods {#Sec2}
=======

The study protocol was composed according to the most recent CONSORT 2010 recommendations for transparent reporting of RCTs \[[@CR12], [@CR13]\]. The study protocol according to the CONSORT recommendations has been published previously \[[@CR14]\].

Ethics and Trial Registration {#Sec3}
-----------------------------

This RCT was approved in May 22, 2009 by the ethics institutional review board at Hannover Medical School, Germany, under the German title "Stosswellentherapie und Krafttraining zur Therapie der Cellulite---eine randomsiert-kontrollierte Studie" (Nr. 5206). The study is internationally registered at ClinicalTrials.gov with ClinicalTrials.gov identifier: NCT00947414.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study and for the publication of patient photographs.

Study Design {#Sec4}
------------

This was a single-center, double-blinded, RCT with a 1:1 parallel group randomization.

Participants {#Sec5}
------------

The mean age of the enrolled participants was 41.4 years in the intervention group and 45.0 years in the control group. BMI (mean ± SE) was 24.2 ± 3.2 kg/m^2^ in the intervention group and 25.3 ± 4.5 kg/m^2^ in the control group.

Eligible patients were females aged between 18 and 65 years with documented cellulite 0° to 3° according to the Nürnberger Müller score \[[@CR1]\]. Exclusion criteria were the following: suspected or evident pregnancy, no cellulite, no informed consent, and age under 18 years or above 65 years. Patients were recruited by advertisements in local regional newspapers and via the Internet. The patient enrollment flow chart according to the CONSORT statement is outlined in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1CONSORT patient flow chart. Modified with permission from Knobloch et al. \[[@CR14]\]

Interventions {#Sec6}
-------------

In CelluShock-2009 patients were randomly assigned with a 1:1 ratio to either ESWT with 0.35 mJ/mm^2^ in the intervention group or 0.01 mJ/mm^2^ in the SHAM-ESWT group. Both groups additionally participated in a home-based, daily gluteal thigh exercise program.

The intervention group received six sessions of ESWT (every 1--2 weeks) with focused shock waves (2,000 impulses, 0.35 mJ/mm^2^, Fig. [2](#Fig2){ref-type="fig"}) plus home-based, daily gluteal strength exercises (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}). The control group received six sessions of SHAM-ESWT (2,000 impulses, 0.01 mJ/mm^2^, every 1--2 weeks) plus home-based, daily gluteal strength exercises. Extracorporeal shock wave therapy was applied using a STORZ focused Duolith machine (Taegerwilen, Suisse) as acoustic wave treatment.Fig. 2Placement of the shockwave probe from distal to proximal on both thighsFig. 3First exercise (15 repetitions per leg twice a day over 12 weeks)Fig. 4Second exercise (15 repetitions per leg twice a day over 12 weeks)

In order to increase the motivation of the participating females, especially in terms of follow-up, we added a daily, home-based gluteal strength exercise program. Twice a day (in the morning and the evening), two different exercises focusing on the gluteal muscles involving the piriformis, the gemelli, and the gluteal muscles were performed with 15 repetitions for each leg (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). The compliance to the daily gluteal workout program was noted in a exercise log to improve and supervise participants' compliance, respectively.

Primary and Secondary Outcome Measures {#Sec7}
--------------------------------------

The primary endpoint, with respect to efficacy of the combined ESWT and gluteal strength exercises versus SHAM-ESWT and the same gluteal strength exercise program, was the change on digital photographs 3 months after the last ESWT treatment assessed by the validated CSS \[[@CR15]\]. This provided reliable, comprehensive, and reproducible results. Cellulite severity may be classified according to the result of this assessment in the CSS in three degrees, as described in Table [2](#Tab2){ref-type="table"}.Table 2Cellulite Severity Scale of mild, moderate or severe degreeCellulite Severity ScaleNew classification1--5Mild6--10Moderate11--15Severe

The classification was performed based on standardized photographs taken by a professional medical photographer at baseline and 12 weeks after the last ESWT treatment in both groups. The assessment of the anonymous digital images was carried out by two blinded assessors who were not aware of either the study arm or the fact that it is a baseline or a follow-up photograph taken 12 weeks after the last ESWT treatment in both groups.

In order to overcome the problems of interpretation associated with multiplicity of analyses we decided to choose the aforementioned clinical endpoint which is a visual one as the primary endpoint and results as secondary endpoints in CelluShock.

Secondary endpoints of the CelluShock RCT were as follows: change of circumference of the thigh (cm), skin elasticity using the Cutometer^®^ (Cutometer MPA 580, Kosmetik Konzept KOKO GmbH & Co KG, Leichlingen, Germany) \[[@CR16]--[@CR19]\], and self-assessment of the success on a visual analogue scale 0--10 (0 = no change, 10 = fully satisfied).

All patients were measured at baseline and after 12 weeks regarding the primary and all secondary endpoints.

Power Calculation {#Sec8}
-----------------

To detect at least a change of two points in the CSS of cellulite, with a two-sided, 5% significance with an 80% power, a sample size of 26 participants with an estimated drop-out rate of 15% was calculated. This was done prior to the start of trial.

Randomization and Allocation Sequence {#Sec9}
-------------------------------------

For allocation of participants, a 1:1 ratio randomization was performed using opaque envelopes for the concealment of allocation. The allocation sequence was concealed from the researcher (BJ) enrolling and assessing participants in sequentially numbered, opaque, sealed envelopes \[[@CR20]\].

Blinding {#Sec10}
--------

Blinding was achieved for all participants enrolled in the trial, the photographer taking the digital images for the primary outcome measure, the two assessors of the outcome measures, all additional health care providers, and for the analyst from the biometrical department. Only one researcher (BJ) was aware of the group assignment performing the randomization and the ESWT.

The assessment of the primary and secondary outcomes was performed by blinded assessors independently from each other, unaware whether the digital image displayed was before or after therapy or with group (intervention or control group) was randomized.

Statistical Analysis {#Sec11}
--------------------

The primary endpoint was change of CSS assessed on digital, standardized photographs by two independent expert examiners. Student's *t* test was applied for parametric data, the Wilcoxon test for non-parametric data, and a level of *P* \< 0.05 was reported as significant. An intention-to-treat analysis was applied. SPSS (IBM Corp., New York, USA) was used to carry out the analysis.

CONSORT Flow Chart {#Sec12}
------------------

Figure [1](#Fig1){ref-type="fig"} highlights the patient flow throughout the CelluShock-2009 RCT (Fig. [1](#Fig1){ref-type="fig"}).

Results {#Sec13}
=======

Primary Outcome Measure---Cellulite Severity Scale {#Sec14}
--------------------------------------------------

The CSS (mean ± SE) in the intervention group was 10.9 ± 3.8 before and 8.3 ± 4.1 after the combined ESWT and strength exercise intervention (*P* = 0.001, 2.53 improvement (+24%), 95% CI 1.43--3.62) (Figs. [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}; Table [3](#Tab3){ref-type="table"}). The CSS in the control group was 10.0 ± 3.8 before and 10.1 ± 3.8 after the SHAM-ESWT and strength exercise intervention (*P* = 0.876, 95% CI −1.1 to 0.97). The change of the CSS in the intervention group versus the control group was significantly different (*P* = 0.001, −24.3 effect size, 95% −36.5 to −12.1).Fig. 5Improvement of the Cellulite Severity Score from 15 to 7 in a female patient suffering from cellulite before and 3 months after six sessions of focused extracorporeal shockwave therapy (0.35 mJ/mm^2^)Fig. 6Improvement of the Cellulite Severity Score from 12 to 2 in a female patient suffering from cellulite before and 3 months after six sessions of focused extracorporeal shockwave therapy (0.35 mJ/mm^2^)Fig. 7Improvement of the Cellulite Severity Score from 10 to 6 in a female patient suffering from cellulite before and 3 months after six sessions of focused extracorporeal shockwave therapy (0.35 mJ/mm^2^)Fig. 8No significant improvement of the Cellulite Severity Score from 13 to 11 in a female patient suffering from cellulite before and 3 months after six sessions of sham extracorporeal shockwave therapy (0.01 mJ/mm^2^, control group)Fig. 9No improvement of the Cellulite Severity Score from 4 to 5 in a female patient suffering from cellulite before and 3 months after six sessions of sham extracorporeal shockwave therapy (0.01 mJ/mm^2^, control group)Fig. 10Change of the Cellulite Severity Score before and 3 months after six sessions of either focused extracorporeal shockwave therapy (ESWT) (0.35 mJ/mm^2^, intervention group) or SHAM-ESWT (0.01 mJ/mm^2^, control group)Table 3Number of patients in each group according to the Cellulite Severity Scale in the intervention and the control group prior and after the interventionCellulite Severity ScaleIntervention groupControl groupBaselinePost-interventionBaselinePost-intervention1--5 (mild)46326--10 (moderate)81291211--15 (severe)13797

The results for the five items of the CSS, the cutometer data, and the thigh circumferences are reported below; all values are given as mean ± SE unless otherwise stated.

Number of Depressions {#Sec15}
---------------------

The number of depressions in the intervention group was 2.2 ± 0.8 at baseline and 1.8 ± 0.9 at follow-up (*P* = 0.001, improvement 0.41, 95% CI 0.17--0.65). The number of depressions in the control group was 2.0 ± 0.8 at baseline and 2.0 ± 0.7 at follow-up (*P* = 0.534, 95% CI −0.30 to 0.16). The change of the number of depressions in the intervention versus the control group was significantly different (*P* = 0.012, −20.0 effect size, 95% CI −34.8 to −4.4).

Depth of Depressions {#Sec16}
--------------------

The depth of depressions in the intervention group was 2.2 ± 0.8 at baseline and 1.6 ± 0.8 at follow-up (*P* = 0.001, 0.61 improvement, 95% CI 0.39--0.84). The depth of depressions in the control group was 2.0 ± 0.8 at baseline and 2.0 ± 0.7 at follow-up (*P* = 1.0, 95% CI −0.24 to 0.24). The change of the depth of depressions in the intervention group versus the control group was significantly different (*P* = 0.001, −31.3 effect size, 95% CI −46.0 to −16.6).

Morphological Appearance of Skin Surface Alterations {#Sec17}
----------------------------------------------------

The morphological appearance of skin surface alterations in the intervention group was 2.2 ± 0.8 at baseline and 1.6 ± 0.8 at follow-up (*P* = 0.001, 0.6 improvement, 95% 0.36--0.8). The morphological appearance of skin surface alterations in the control group was 1.9 ± 0.8 at baseline and 1.9 ± 0.6 at follow-up (*P* = 0.837, 95% CI −0.20 to 0.25). The change of the morphological appearance of skin surface alterations in the intervention group versus the control group was significantly different (*P* = 0.007, −16.6 effect size, 95% CI −28.7 to −4.6).

Grade of Laxity, Flaccidity or Sagging Skin {#Sec18}
-------------------------------------------

The grade of laxity, flaccidity or sagging skin in the intervention group was 2.2 ± 0.8 at baseline and 1.6 ± 0.8 at follow-up (*P* = 0.001, 0.5 improvement, 95% CI 0.27--0.73). The grade of laxity, flaccidity or sagging skin in the control group was 2.0 ± 0.9 at baseline and 2.1 ± 0.8 at follow-up (*P* = 0.516, 95% CI −0.34 to 0.17). The change of the grade of laxity, flaccidity or sagging skin in the intervention group versus the control group was significantly different (*P* = 0.001, −25.1 effect size, 95% CI −39.6 to −10.6).

Classification Scale by Nürnberger and Müller {#Sec19}
---------------------------------------------

The classification scale by Nürnberger and Müller in the intervention group was 2.2 ± 0.8 at baseline and 1.8 ± 0.9 at follow-up (*P* = 0.001, 0.5 improvement, 95% CI 0.3--0.8). The classification scale by Nürnberger and Müller in the control group was 2.1 ± 0.8 at baseline and 2.1 ± 0.7 at follow-up (*P* = 1.0, 95% CI −0.22 to 0.22). The change of the classification scale by Nürnberger and Müller in the intervention group versus the control group was significantly different (*P* = 0.043, −24.4 effect size, 95% CI −37.7 to −11.1).

Change of Circumference of the Thigh and Body Mass Index {#Sec20}
--------------------------------------------------------

The change of thigh circumference in the intervention group was 61.5 ± 6.2 cm at baseline to 61.0 ± 5.9 cm at follow-up (*P* = 0.760, 95% CI −2.91 to 3.97). There was no change of thigh circumference in the control group (61.6 ± 6.9 cm) at baseline versus follow-up (61.6 ± 6.9 cm; *P* = 0.996; 95% CI −4.28 to 4.31). Pre- and post-treatment body weight index did not change in either group significantly beyond 3%.

Skin Elasticity Using the Cutometer^®^ {#Sec21}
--------------------------------------

The skin elasticity in the intervention group was 14.1 ± 2.5% at baseline and 14.1% ± 1.6 at follow-up (*P* = 0.963; 95% CI −1.22 to 1.16).

The skin elasticity in the control group was 14.4% ± 1.8 at baseline and 14.1% ± 1.9 at follow-up (*P* = 0.676; 95% CI −0.91 to 1.38).

Discussion {#Sec22}
==========

The combination of focused ESWT (0.35 mJ/mm^2^, 2,000 impulses, 6 sessions) in combination with gluteal strength training was superior to a gluteal strength training alone in terms of the CSS in a 3-month perspective. The significant mean improvement was 24% in the intervention group in contrast to the control group, a clinically meaningful difference. Second, the SHAM-ESWT and the gluteal strength training were not able to change the CSS.

The strengths of this double-blinded, randomized clinical trial are the independent assessment by two expert examiners who were blinded to both the patients and the group allocation. Both experts assessed the digitalized standardized photographs independently and the mean of both assessments was applied. Second, this is the first registered, double-blinded, randomized clinical trial to assess the effects of a gluteal strength training and the combination with focused ESWT. Third, standardized photographs were taken by a clinical photographer independently from the study team. Fourth, the control group received SHAM-ESWT (0.01 mJ/mm^2^, 2,000 impulses, 6 sessions) which did not appear to have any clinical effect in terms of the CSS at all, with identical values before and after the intervention.

However, to date we cannot estimate the long-term efficacy and sustainability of the aforementioned clinical effects in a perspective of one or more years. It is possible that, after a year, an additional treatment might be warranted, such as a touch-up procedure. In our personal experience, select cases might benefit even longer than 1 year from a set of six focused shockwave sessions, but this is only a non-controlled observation.

The results of this randomized clinical study should be discussed in detail. The CSS is a validated photo-numeric Cellulite Severity Scale, which has been published in 2009 by Dr. Hexsel and coworkers \[[@CR15]\]. Beyond the well-known Nürnberger and Müller score ranging from 0° to 3°, this validated score appears to better reflect even modest to small changes of a given therapeutic intervention. The CSS has a high intraclass correlation coefficient of 0.9 or more and ranges from 1 to 15. Three clinical cellulite severity grades have been proposed by Hexsel et al. \[[@CR15]\] (Table [2](#Tab2){ref-type="table"}). Given our patients, we included the majority of patients with moderate to severe degrees of cellulite. This is partially reflected by the mean age beyond 40 years and the BMI beyond 24.2 kg/m^2^ in both groups.

As far as the underlying mechanisms of the evident improvements in the CSS are concerned, a "mechanical" response might be evident as well as a "regenerative" response of the afflicted skin.

In terms of the "mechanical" perspective, one might speculate that the focused extracorporeal shockwave has somewhat disrupted either the fat components or the septae or both, which might lead to a smoothening of the afflicted skin. MR imaging has shown that fibrous septa are visualized in 97% of the area with cellulite depressions, which are markedly thickened in cellulite afflicted areas \[[@CR21]\]. Shockwave energy might have weakened the fibrous septae and thus the afflicted skin became smoother.

Reduction of lymphedema is a second potential underlying mechanism. Recently, a significant reduction of lymphedema was reported clinically following four ESWT sessions in females with secondary lymphedema following breast cancer treatment \[[@CR6]\]. In animal experiments ESWT and the vascular endothelial growth factor (VEGF-C) hydrogel appear to exert a synergistic effect in promoting lymphangiogenesis \[[@CR22]\].

On the other hand, ESWT might somewhat influence mesenchymal stem cells. There is evolving experimental data suggesting that shockwave therapy activation pathways in adipose-derived stem cells \[[@CR23]\]. Clinically, diseased skin appears to normalize following shockwave treatment such as in progressive systemic sclerosis with an up regulation of endothelial progenitor cells and circulating endothelial cells \[[@CR24]\].

Energy flux density of the focused ESWT is another issue to concern. We used low to medium energy flux densities of 0.35 mJ/mm^2^ with 1,000 impulses on each thigh with 4 Hz. To date, we do not know in controlled trials whether potentially higher energy flux densities such as up to 1.24 mJ/mm^2^ might be even more beneficial in terms of the potential disruption of the fibrous septae in the cellulite-afflicted areas. On the other hand, stem-cell activation might be achieved by rather low-energy flux densities in regard of the aforementioned potential underlying "regenerative" mechanisms.

To date, only small size, controlled trials with wide CIs have been published \[[@CR7], [@CR25]\]. We tried to overcome the methodological shortcomings of previous trials in CelluShock-2009. In regard to different techniques, there are evolving clinical data that, for example, low-level laser therapy with 532 nm wave lengths appears to improve cellulite in a double-blind, placebo-controlled, randomized trial \[[@CR26]\]. 1,064 nm Nd:YAG laser appears to improve mild to moderate cellulite also \[[@CR27]\]. Radiofrequency is able to reduce cellulite in a randomized trial \[[@CR28]\].

Limitations {#Sec23}
-----------

Given our randomized, double-blinded clinical trial, some limitations have to be considered when interpreting our data. First, the extent of cellulite reflected by digital unprocessed images assessed by two independent examiners was chosen to overcome some types of biases. However, a digital image does not necessarily reflect or even replace a clinical examination including a pinch test. However, we sought to address as objective as possible the outcome based on digital images. Those images were produced by a clinical plastic surgical professional photographer under the very same circumstances to overcome issues such as angle of the photograph, lighting, among others. To date, we can only report the short-term results 3 months following ESWT. We do not know the long-term effects in terms of efficacy and sustainability of six sessions of focused ESWT in cellulite to date.

Conclusion {#Sec24}
==========

The combination of focused ESWT (0.35 mJ/mm^2^, 2,000 impulses, 6 sessions) with gluteal strength training was superior to SHAM-ESWT and gluteal strength training in moderate to severe cellulite in terms of the CSS in a RCT. The mean improvement was 24% in the intervention in contrast to the control group. Second, the SHAM-ESWT and gluteal strength training were not able to change the CSS in a 3-month perspective. Long-term data are warranted to elucidate the sustainability of the aforementioned clinical effects.
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